2023
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. The Oncologist 2023, 28: e973-e976. PMID: 37656608, PMCID: PMC10546821, DOI: 10.1093/oncolo/oyad249.Peer-Reviewed Original ResearchConceptsHER2 mRNA levelsIHC 0MRNA levelsOncotype DX recurrence score resultsEstrogen receptor-positive breast cancerReceptor-positive breast cancerCurrent adjuvant chemotherapyOncotype DX assayRecurrence Score resultsPositive breast cancerInvasive breast carcinomaIHC score 0Adjuvant chemotherapyQuantitative RT-PCRBreast carcinomaPositive statusScore 0Breast cancerStage IYale cohortHigher mRNA levelsCancerRT-PCRPatientsHER2Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
Danziger N, Sokol E, Graf R, Hiemenz M, Maule J, Parimi V, Palmieri C, Pusztai L, Ross J, Huang R. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. The Oncologist 2023, 28: 319-326. PMID: 36866462, PMCID: PMC10078903, DOI: 10.1093/oncolo/oyad025.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerPD-L1 expressionNegative triple negative breast cancerTNBC tissue samplesPD-L1 positivityPD-L1Dako 22C3Breast cancerDeath ligand 1 (PD-L1) immunohistochemistry (IHC) assaysPD-L1 groupNon-TNBC patientsTissue samplesComprehensive genomic profilingBreast cancer subtypesFoundationOne CDxImmunotherapy efficacyMetastatic sitesTNBC casesBC patientsBreast carcinomaPositive statusImmunohistochemistry assaysOptimum cutoffCancer subtypesGenomic profiling
2022
The mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Fischbach N, Huang R, Lustberg M, Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Journal Of Clinical Oncology 2022, 40: 1025-1025. DOI: 10.1200/jco.2022.40.16_suppl.1025.Peer-Reviewed Original ResearchTriple-negative breast cancerComprehensive genomic profilingMetastatic breast cancerBreast cancerClinical trialsPathology reportsMutational profileHER2- metastatic breast cancerConsecutive breast cancersAnti-estrogen therapyNegative breast cancerPD-L1 IHCPotential therapeutic implicationsHigh rateEndocrine therapyEstrogen therapyPatient ageFoundation MedicineKRAS alterationsRare subtypeHER2 expressionClinical behaviorReceptor phenotypeBreast carcinomaTreatment strategies
2021
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
Huang RSP, Haberberger J, McGregor K, Mata DA, Decker B, Hiemenz MC, Lechpammer M, Danziger N, Schiavone K, Creeden J, Graf RP, Strowd R, Lesser GJ, Razis ED, Bartsch R, Giannoudis A, Bhogal T, Lin NU, Pusztai L, Ross JS, Palmieri C, Ramkissoon SH. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. The Oncologist 2021, 26: 835-844. PMID: 34105210, PMCID: PMC8488784, DOI: 10.1002/onco.13855.Peer-Reviewed Original ResearchConceptsComprehensive genomic profilingPD-L1 immunohistochemistryBrain metastasesTumor mutational burdenPrimary breast carcinomaRelevant genomic alterationsBreast carcinomaPrimary tumorHigh prevalenceMutational burdenCerebrospinal fluidTissue acquisitionCatalytic polypeptide-like (APOBEC) mutational signatureGenomic alterationsPrimary breast carcinoma specimensHigh tumor mutational burdenGenomic profilingTriple-negative breast carcinomaTNBC brain metastasisCohort of patientsBrain metastasis samplesBreast carcinoma specimensHigher positive rateHigh microsatellite instabilityApolipoprotein B mRNA editing enzyme
2016
Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer
Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB, Pusztai L, Rimm DL. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Research 2016, 18: 78. PMID: 27473061, PMCID: PMC4966732, DOI: 10.1186/s13058-016-0737-x.Peer-Reviewed Original ResearchConceptsIntraclass correlation coefficientQuantitative immunofluorescenceBreast cancerSame cancerSingle biopsyMultiplexed quantitative immunofluorescenceTumor-infiltrating lymphocytesPotential predictive markerPrimary breast carcinomaCytokeratin-positive epithelial cellsCD20-positive lymphocytesCD8 levelsLymphocyte scoreQIF scoresLymphocyte countLymphocyte subpopulationsMultiple biopsiesSubpopulation countsPredictive markerPrognostic informationBreast carcinomaBiopsyB lymphocytesCD3Breast tumors
2015
Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma
Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. British Journal Of Cancer 2015, 113: 1003-1009. PMID: 26393887, PMCID: PMC4651124, DOI: 10.1038/bjc.2015.308.Peer-Reviewed Original ResearchConceptsNon-metastatic breast cancerBreast cancerClinical nomogramCox proportional hazards regression modelProportional hazards regression modelsBone-targeted therapiesHormone receptor statusEarly breast cancerLymph node statusLymphovascular space invasionEarly breast carcinomaAnalysis of patientsHazards regression modelsPathologic variablesReceptor statusDistant metastasisTumor characteristicsNode statusSpace invasionT classificationPatient populationMedical recordsBreast carcinomaCommon siteConcordance index
2012
Survival outcomes in HER2-positive invasive lobular breast carcinoma.
Barcenas C, Hess K, Delpech Y, Pusztai L, Hortobagyi G, Giordano S, Esteva F. Survival outcomes in HER2-positive invasive lobular breast carcinoma. Journal Of Clinical Oncology 2012, 30: 612-612. DOI: 10.1200/jco.2012.30.15_suppl.612.Peer-Reviewed Original ResearchInvasive lobular breast carcinomaDisease-free survivalER/PRInvasive ductal carcinomaLobular breast carcinomaSurvival outcomesOverall survivalBreast carcinomaCox proportional hazards regressionMD Anderson Cancer CenterProgesterone receptor statusRare clinical entityBreast cancer patientsProportional hazards regressionNumber of patientsAnderson Cancer CenterMedian followBetter OSMedian ageReceptor statusClinical entityDuctal carcinomaHazards regressionCancer CenterLobular carcinoma
2010
Stability of estrogen receptor status in breast carcinoma
Gong Y, Han EY, Guo M, Pusztai L, Sneige N. Stability of estrogen receptor status in breast carcinoma. Cancer 2010, 117: 705-713. PMID: 20939012, DOI: 10.1002/cncr.25506.Peer-Reviewed Original ResearchConceptsER statusBreast carcinomaEndocrine therapyMetastatic sitesPrimary tumorMetastatic tumorsMetastatic breast carcinomaEstrogen receptor statusER discordanceDisease courseReceptor statusSystemic therapyClinical courseER expressionER testingClinical managementNegative conversionER assaysDiscordant casesCarcinomaPositive conversionTumorsPatientsMetastasisTherapy
2005
Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma
Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma. Cancer 2005, 104: 682-691. PMID: 15986399, DOI: 10.1002/cncr.21227.Peer-Reviewed Original ResearchConceptsAdministration of tariquidarP-gp expressionSestamibi scanBreast carcinomaSestamibi uptakeP-gp-positive tumorsTaxane-containing chemotherapy regimensDocetaxel-related toxicitiesLimited clinical activityObjective tumor responsePercent of patientsPhase II studyAdvanced breast carcinomaP-glycoprotein inhibitor tariquidarP-glycoprotein inhibitorsMultidrug resistance modulationP-gp transporterMultidrug resistance inhibitorsSame chemotherapyStable diseaseChemotherapy regimenChemotherapy regimensTaxane chemotherapyClinical responseDose modificationEpidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin‐based neoadjuvant chemotherapy
Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin‐based neoadjuvant chemotherapy. Cancer 2005, 104: 676-681. PMID: 15981280, DOI: 10.1002/cncr.21217.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCyclophosphamideDisease-Free SurvivalDoxorubicinErbB ReceptorsFemaleFluorouracilHumansImmunohistochemistryNeoadjuvant TherapyPrognosisRandomized Controlled Trials as TopicSurvival AnalysisConceptsEpidermal growth factor receptorBreast carcinomaEGFR expressionAnthracycline chemotherapyLymph nodesEpidermal growth factor receptor expression correlatesSurvival ratePathologic complete response ratePretreatment tumor tissue samplesDisease-free survival ratesCox regression analysis modelComplete response rateEGFR-negative tumorsEGFR-positive diseasePositive lymph nodesAdvanced breast carcinomaMore lymph nodesOutcomes of patientsOverall survival rateProgesterone receptor statusEGFR-positive tumorsTumor tissue samplesKnowledge of outcomesGrowth factor receptorCyclophosphamide chemotherapySignificant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry
Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Research And Treatment 2005, 89: 149-157. PMID: 15692757, DOI: 10.1007/s10549-004-1710-4.Peer-Reviewed Original ResearchConceptsBreast cancer patientsCancer patientsBreast cancerHealthy volunteersNoncancerous breastHealthy womenProtein expressionEarly-stage breast cancerUnilateral invasive breast carcinomaCancer-bearing breastsUnilateral breast cancerNAF samplesInvasive breast carcinomaBreast cancer screeningHealthy female volunteersPrimary carcinomaCancer screeningSurface-enhanced laser desorption ionization mass spectrometryBreast carcinomaTumor markersPatientsStage IFemale volunteersProtein chip arraysBreast
2004
Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma
Gonzalez‐Angulo A, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004, 101: 258-263. PMID: 15241821, DOI: 10.1002/cncr.20348.Peer-Reviewed Original ResearchConceptsEarly-stage breast carcinomaBreast carcinomaTumor specimensPathologic responseStage II breast carcinomaAJCC stage IIMedian patient ageStage III diseasePathologic complete responseOverall survival rateLack of associationGene amplificationPreoperative chemotherapyRecurrent diseaseComplete responsePatient agePatientsCarcinomaSurvival rateTissue specimensStage IITaxanesHormone receptorsTumorsDiseasePharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL, Drake RR, Vlahou A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004, 100: 1814-1822. PMID: 15112261, DOI: 10.1002/cncr.20203.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsy, NeedleBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFemaleFluorouracilHumansMastectomyMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelPostoperative CarePreoperative CareProteomicsRisk AssessmentSensitivity and SpecificitySurvival AnalysisTreatment OutcomeConceptsBreast carcinomaHealthy womenPreoperative chemotherapyFinal tumor responseSubset of patientsDay 3 posttreatmentAdjuvant chemotherapyPostoperative chemotherapyCyclophosphamide chemotherapyFAC chemotherapyMicrometastatic diseasePaclitaxel chemotherapyNormal womenTumor responsePlasma profilesHealthy volunteersChemotherapyPatientsStage ICarcinomaDay 0Single courseWomenPlasma samplesCandidate markersCorrelation between response to neoadjuvant chemotherapy (NACT) with single agent taxanes and HER-2 gene amplification in patients with breast carcinoma
Gonzalez-Angulo A, Krishnamurthy S, Yamamura Y, Pusztai L, Buzdar A, Hortobagyi G, Esteva F. Correlation between response to neoadjuvant chemotherapy (NACT) with single agent taxanes and HER-2 gene amplification in patients with breast carcinoma. European Journal Of Cancer Supplements 2004, 2: 70. DOI: 10.1016/s1359-6349(04)90651-9.Peer-Reviewed Original ResearchChange in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal‐Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 2004, 100: 1365-1373. PMID: 15042669, DOI: 10.1002/cncr.20134.Peer-Reviewed Original ResearchConceptsResidual tumor sizeCore needle biopsyNeoadjuvant chemotherapyTumor sizeResection specimensNeedle biopsyBreast carcinomaTumor cellularityClinical responsePathologic responseControl groupDiagnostic core needle biopsyGreatest dimensionPrimary surgical managementResidual primary tumorResidual tumor categoriesComplete pathologic responseWeeks of diagnosisResidual tumor groupEosin-stained tissue sectionsCyclophosphamide chemotherapyPartial responsePathologic assessmentPathologic evaluationPathologic sizePrognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma
Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma. Cancer 2004, 100: 499-506. PMID: 14745865, DOI: 10.1002/cncr.11940.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsy, NeedleBreast NeoplasmsCombined Modality TherapyFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryLymph NodesMastectomyMiddle AgedMitogen-Activated Protein KinasesNeoplasm StagingP38 Mitogen-Activated Protein KinasesProbabilityPrognosisProportional Hazards ModelsReceptor, ErbB-2Risk AssessmentSensitivity and SpecificitySurvival AnalysisTreatment OutcomeConceptsLymph node positive breast carcinomaNode-positive breast carcinomaProgression-free survivalP-p38 MAPKShorter progression-free survivalHER-2 expressionP-p38 MAPK expressionBreast carcinomaAdjuvant chemotherapyMAPK expressionKi-67Phosphorylated p38 MAPK expressionInitial cancer surgeryPrimary breast carcinomaInvasive breast carcinomaP38 MAPK expressionP38 mitogen-activated protein kinase phosphorylationPhosphorylated p38 mitogen-activated protein kinaseMitogen-activated protein kinase phosphorylationBreast carcinoma cellsAdjuvant fluorouracilMedian followCyclophosphamide chemotherapyCancer surgeryPoor outcome
2003
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical Cancer Research 2003, 9: 5652-9. PMID: 14654548.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCell Cycle ProteinsCOP9 Signalosome ComplexCyclin-Dependent Kinase Inhibitor p27DNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsLymphatic MetastasisMiddle AgedPeptide HydrolasesReceptor, ErbB-2Receptors, EstrogenSurvival AnalysisTime FactorsTranscription FactorsTumor Suppressor ProteinsConceptsNode-negative breast cancerAdjacent normal tissuesInvasive breast carcinomaBreast cancerJab1 overexpressionNormal tissuesBreast carcinomaAdjuvant systemic therapyDisease-free survivalIndependent prognostic factorInvasive breast cancerLow nuclear gradeBreast cancer tissuesExpression levelsProtein-1 expressionBreast tumor tissuesWestern blot analysisDomain-binding protein 1Patient agePrognostic factorsSystemic therapyPrognostic significanceTumor sizeNuclear gradeInvasive tumorsTotal RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma
Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma. Cancer 2003, 97: 2960-2971. PMID: 12784330, DOI: 10.1002/cncr.11435.Peer-Reviewed Original ResearchConceptsGene expression profilesTranscriptional profilesExpression profilesFine-needle aspiration biopsyGenomic databasesStromal gene expressionGene expressionTotal RNA yieldTotal RNABreast carcinomaTumor cell populationSubset of genesCDNA microarray analysisStromal cellsBiopsy samplesGene expression profilingCell populationsMicroscopic cell countsRNA yieldAspiration biopsyGenomic studiesTranscriptional profilingCDNA microarrayNonlymphoid stromal cellsExpression profilingCorrelation between HER‐2 expression and response to neoadjuvant chemotherapy with 5‐fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma
Zhang F, Yang Y, Smith T, Kau S, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L. Correlation between HER‐2 expression and response to neoadjuvant chemotherapy with 5‐fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 2003, 97: 1758-1765. PMID: 12655533, DOI: 10.1002/cncr.11245.Peer-Reviewed Original ResearchConceptsCourses of FACBreast carcinomaNeoadjuvant chemotherapyPathologic responseResponse rateLymph node-positive diseaseGood pathologic responseMedian patient ageClinical response rateNode-positive diseasePercent of patientsTime of surgeryClinical laboratory assessmentsMinimal residual diseaseClinical responsePositive diseasePathologic assessmentPatient agePhysical examinationPositive tumorsResidual diseaseImaging assessmentClinical assessmentResponse assessmentNonsignificant trend